These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 24770979)

  • 1. [New AHA and ACC guidelines on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk : Statement of the D•A•CH Society for Prevention of Cardiovascular Diseases, the Austrian Atherosclerosis Society and the Working Group on Lipids and Atherosclerosis (AGLA) of the Swiss Society for Cardiology].
    Klose G; Beil FU; Dieplinger H; von Eckardstein A; Föger B; Gouni-Berthold I; Koenig W; Kostner GM; Landmesser U; Laufs U; Leistikow F; März W; Merkel M; Müller-Wieland D; Noll G; Parhofer KG; Paulweber B; Riesen W; Schaefer JR; Steinhagen-Thiessen E; Steinmetz A; Toplak H; Wanner C; Windler E
    Internist (Berl); 2014 May; 55(5):601-6. PubMed ID: 24770979
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Eligibility for PCSK9 Inhibitors According to American College of Cardiology (ACC) and European Society of Cardiology/European Atherosclerosis Society (ESC/EAS) Guidelines After Acute Coronary Syndromes.
    Gencer B; Koskinas KC; Räber L; Karagiannis A; Nanchen D; Auer R; Carballo D; Carballo S; Klingenberg R; Heg D; Matter CM; Lüscher TF; Rodondi N; Mach F; Windecker S
    J Am Heart Assoc; 2017 Nov; 6(11):. PubMed ID: 29122809
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cholesterol treatment and changes in guidelines in an academic medical practice.
    Schoen MW; Salas J; Scherrer JF; Buckhold FR
    Am J Med; 2015 Apr; 128(4):403-9. PubMed ID: 25460526
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Eligibility for PCSK9 inhibitors based on the 2019 ESC/EAS and 2018 ACC/AHA guidelines.
    Koskinas KC; Gencer B; Nanchen D; Branca M; Carballo D; Klingenberg R; Blum MR; Carballo S; Muller O; Matter CM; Lüscher TF; Rodondi N; Heg D; Wilhelm M; Räber L; Mach F; Windecker S
    Eur J Prev Cardiol; 2021 Mar; 28(1):59-65. PubMed ID: 33755142
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The ACC/AHA 2013 guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular disease risk in adults: the good the bad and the uncertain: a comparison with ESC/EAS guidelines for the management of dyslipidaemias 2011.
    Ray KK; Kastelein JJ; Boekholdt SM; Nicholls SJ; Khaw KT; Ballantyne CM; Catapano AL; Reiner Ž; Lüscher TF
    Eur Heart J; 2014 Apr; 35(15):960-8. PubMed ID: 24639424
    [TBL] [Abstract][Full Text] [Related]  

  • 6. New AHA and ACC guidelines on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk.
    Klose G; Beil FU; Dieplinger H; von Eckardstein A; Föger B; Gouni-Berthold I; Heigl F; Koenig W; Kostner GM; Landmesser U; Laufs U; Leistikow F; März W; Noll G; Parhofer KG; Paulweber B; Riesen WF; Schaefer JR; Steinhagen-Thiessen E; Steinmetz A; Toplak H; Wanner C; Windler E;
    Wien Klin Wochenschr; 2014 Mar; 126(5-6):169-75. PubMed ID: 24615676
    [TBL] [Abstract][Full Text] [Related]  

  • 7. How effective are the ESC/EAS and 2013 ACC/AHA guidelines in treating dyslipidemia? Lessons from a lipid clinic.
    Barkas F; Milionis H; Kostapanos MS; Mikhailidis DP; Elisaf M; Liberopoulos E
    Curr Med Res Opin; 2015 Feb; 31(2):221-8. PubMed ID: 25418708
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Systematic Review for the 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.
    Wilson PWF; Polonsky TS; Miedema MD; Khera A; Kosinski AS; Kuvin JT
    J Am Coll Cardiol; 2019 Jun; 73(24):3210-3227. PubMed ID: 30423394
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [ECS guidelines 2016 - dyslipidaemias].
    Sinning D; Landmesser U
    Herz; 2016 Dec; 41(8):671-676. PubMed ID: 27844136
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Population Effect of Differences in Cholesterol Guidelines in Eastern Europe and the United States.
    Lee JC; Zdrojewski T; Pencina MJ; Wyszomirski A; Lachacz M; Opolski G; Bandosz P; Rutkowski M; Gaciong Z; Wyrzykowski B; Navar AM
    JAMA Cardiol; 2016 Sep; 1(6):700-7. PubMed ID: 27434662
    [TBL] [Abstract][Full Text] [Related]  

  • 11. American College of Cardiology/American Heart Association (ACC/AHA) Class I Guidelines for the Treatment of Cholesterol to Reduce Atherosclerotic Cardiovascular Risk: Implications for US Hispanics/Latinos Based on Findings From the Hispanic Community Health Study/Study of Latinos (HCHS/SOL).
    Qureshi WT; Kaplan RC; Swett K; Burke G; Daviglus M; Jung M; Talavera GA; Chirinos DA; Reina SA; Davis S; Rodriguez CJ
    J Am Heart Assoc; 2017 May; 6(5):. PubMed ID: 28495699
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Systematic Review for the 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.
    Wilson PWF; Polonsky TS; Miedema MD; Khera A; Kosinski AS; Kuvin JT
    Circulation; 2019 Jun; 139(25):e1144-e1161. PubMed ID: 30586775
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Hypercholesterolemia - Where are we today? Where are we going?].
    Gitt AK; Zahn R
    Herz; 2016 Aug; 41(5):413-20. PubMed ID: 27412663
    [TBL] [Abstract][Full Text] [Related]  

  • 14. AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY GUIDELINES FOR MANAGEMENT OF DYSLIPIDEMIA AND PREVENTION OF CARDIOVASCULAR DISEASE.
    Jellinger PS; Handelsman Y; Rosenblit PD; Bloomgarden ZT; Fonseca VA; Garber AJ; Grunberger G; Guerin CK; Bell DSH; Mechanick JI; Pessah-Pollack R; Wyne K; Smith D; Brinton EA; Fazio S; Davidson M
    Endocr Pract; 2017 Apr; 23(Suppl 2):1-87. PubMed ID: 28437620
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Implications of the 2013 ACC/AHA cholesterol guidelines on contemporary clinical practice for patients with atherosclerotic coronary and peripheral arterial disease.
    Gunasekaran P; Jeevanantham V; Sharma S; Thapa R; Gupta K
    Indian Heart J; 2017; 69(4):464-468. PubMed ID: 28822512
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Statin Use in Primary Prevention of Atherosclerotic Cardiovascular Disease According to 5 Major Guidelines for Sensitivity, Specificity, and Number Needed to Treat.
    Mortensen MB; Nordestgaard BG
    JAMA Cardiol; 2019 Nov; 4(11):1131-1138. PubMed ID: 31577339
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A controversial step forward: A commentary on the 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults.
    Ades PA
    Coron Artery Dis; 2014 Jun; 25(4):360-3. PubMed ID: 24518291
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Guidelines for the management of dyslipidemia].
    Díaz Rodríguez Á;
    Semergen; 2014 Sep; 40 Suppl 4():19-25. PubMed ID: 25595349
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CAC Score Improves Coronary and CV Risk Assessment Above Statin Indication by ESC and AHA/ACC Primary Prevention Guidelines.
    Mahabadi AA; Möhlenkamp S; Lehmann N; Kälsch H; Dykun I; Pundt N; Moebus S; Jöckel KH; Erbel R;
    JACC Cardiovasc Imaging; 2017 Feb; 10(2):143-153. PubMed ID: 27665163
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evidence supporting primary prevention of cardiovascular diseases with statins: Gaps between updated clinical results and actual practice.
    Bruckert E; Ferrières J
    Arch Cardiovasc Dis; 2014 Mar; 107(3):188-200. PubMed ID: 24613429
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.